Authors
Latest:
Dr. Ahn on Link Between Tumor Somatic Variants and Chemo Resistance in Biliary Tract CancerDaniel H. Ahn, MD, assistant professor of Medicine, Mayo Clinic, discusses a next-generation sequencing survey of biliary track cancer to reveal the association between tumor somatic variants and chemotherapy resistance.
Latest:
Dr. Fowler on the Mechanism of Action of T-rapa CellsDaniel H. Fowler, MD, senior investigator, Center for Cancer Research, National Cancer Institute, describes the mechanism of action of T-rapa cells.
Latest:
Daniel H. Galmarini Provides an Overview of Adaptive RadiotherapyDaniel H. Galmarini, Chief Technology Officer/Director, Physics and Engineering, 21st Century Oncology, provides an overview of adaptive radiotherapy.
Latest:
Everyone Loves e-Prescribing! Right?Electronic prescribing is rapidly gaining support from a diverse array of healthcare organizations, government agencies, and technology corporations.
Latest:
Phase II Clinical Trial of Intratumoral Dendritic Cells Injections and Neoadjuvant Radiotherapy in Resectable Soft Tissue SarcomasNeoadjuvant radiation with dendritic cell injections has the potential to be safe, effective, and immunogenic in high-grade soft tissue sarcoma and needs to be confirmed in randomized larger clinical trials.
Latest:
Dr. Daniel Brat on Characterizing Diffuse Lower Grade GliomasDaniel J. Brat, MD, PhD, vice chair, Translational Programs, Department of Pathology and Laboratory Medicine, Emory University School of Medicine, director, Cancer Tissue and Pathology Shared Resource, Winship Cancer Institute, discusses genomic characterization of diffuse lower grade gliomas.
Latest:
Dr DeAngelo on Non-Chemotherapy Treatment Options in CLLDaniel DeAngelo, MD, PhD, discusses how the shift away from chemotherapy has affected the management of chronic lymphocytic leukemia.
Latest:
Future Management of Chronic Myeloid LeukemiaClosing out their discussion on the management of chronic myeloid leukemia, experts share practical advice and excitement for novel strategies.
Latest:
Dr. George on the Importance of Understanding Mutations in Prostate CancerDaniel J. George, MD, discusses the importance of understanding mutations in prostate cancer.
Latest:
Dr. Geynisman on Patient Preferences for Treatment of RCCDaniel M. Geynisman, MD, assistant professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses patient preferences for the treatment of renal cell carcinoma (RCC).
Latest:
Dr. Morgensztern on Advances With Amivantamab in NSCLCDaniel Morgensztern, MD, discusses ongoing research with amivantamab-vmjw in non–small cell lung cancer.
Latest:
Dr. O'Connell on a Phase II Trial to Evaluate Optune in Grade III Brain CancerDaniel O'Connell, MD, University of California at Los Angeles, discusses a phase II trial testing the benefits of tumor treating fields with Optune for bevacizumab-naive patients with grade III malignant glioma.
Latest:
Dr Petrylak on the Shifting Role of Avelumab Maintenance in Metastatic Urothelial CancerDaniel Petrylak, MD, discusses how the FDA approval of enfortumab vedotin plus pembrolizumab impacts the use of avelumab maintenance in urothelial cancer.
Latest:
Dr. Couriel Discusses Treating GVHD With PhotopheresisDr. Daniel Couriel, from the Unversity of Michigan Comprehensive Cancer Center, Discusses Treating GVHD With Photopheresis
Latest:
Dr. Vlock on Anti—CD20 Interleukin-2 Immunocytokine in NHLDaniel R. Vlock, MD, founder and CEO, Alopexx Pharmaceuticals, discusses a phase I/II study of an anti–CD20 interleukin-2 immunocytokine in patients with relapsed/refractory non-Hodgkin lymphoma (NHL).
Latest:
Daniel Sargent on International Collaboration for Colon Cancer ResearchDaniel Sargent, PhD, professor of Oncology and Biostatistics, Mayo Clinic in Rochester, Minnesota, discusses the IDEA initiative, which is an international study to examine if patients with colon cancer would benefit from reducing the duration of adjuvant therapy from 3 months to 6 months to reduce side effects and cost.
